

BEST OF SABCS CROATIA, Zagreb 20. – 21. February 2026.

PROGRAMME

FRIDAY, 20.2.2026.

14:30 Welcome and Introductions

14:40 – 15:50 Section 1.

Z. MARUŠIĆ Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stageII/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181/CompassHER2 pCR trial

M. JAZVIĆ Prognostic Markers in Residual Tumors after Neoadjuvant Chemotherapy (NACT) for Early Triple-Negative Breast Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant GBG/AGO-B trials

S. PLEŠTINA Effect of Adjuvant Carboplatin Intensified Chemotherapy versus Standard Chemotherapy on Survival in Women with High-Risk Early-Stage Triple-Negative Breast Cancer (CITRINE): A Phase 3 Randomized Trial .

J. FLAM Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results From the Phase 3 EMBER-3 Trial

T. SILOVSKI Sacituzumab Govitecan vs Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

15:50 - 16:20

Satellite Symposium: Eli Lilly

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

16:20 – 16:50 Satellite Symposium: Novartis

16:50 – 17:20 Coffee break

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

17:20 – 17:50 Satellite Symposium: Roche

17:50 – 18:50 Section 2.

J. CORTES Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial.

M. BAN Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

A. STRIKIĆ Efficacy Analysis of the Randomized Phase III DETECT Trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2 positive and Hormone Positive Metastatic Breast cancer .

N. ŠARIĆ Radiation therapy or endocrine therapy

18:50 End of program

SATURDAY, 21.2.2026.

9:00 – 10:15 Section 3.

S. TOMIĆ HER2 low/ultralow: what the pathologist sees

B. PETRIĆ MIŠE DESTINY-Breast11 safety: neoadjuvant trastuzumab deruxtecan(T-DXd) alone or followed by paclitaxel + trastuzumab +pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer

A. BUDISAVLJEVIĆ	Trastuzumab deruxtecan vs trastuzumab emtansine in pts with high risk HER2+ primary breast cancer with residual disease after neoadj th: interim analysis of Destiny -Breast 05.
N. DEDIĆ PLAVETIĆ	HER2CLIMB-05: A randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer
P. SERTIĆ	Cardiotoxicity of breast cancer novel therapies
J. JOVIĆ ZLATOVIĆ	Impact of Immune Checkpoint Inhibition on Fertility in Young Women with Early Triple-Negative Breast Cancer receiving neoadjuvant Chemotherapy: A Prospective Substudy of the NSABP B-59/GeparDouzeTrial

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

10:15 – 10:45 Satellite Symposium Novartis

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

10:45 - 11:15 Satellite Symposium Eli Lilly

11:15 – 11:35 Coffee break

11:35 – 12:50 Section 4.

I. MILAS Axillary surgery in breast cancer with one to three sentinel node macrometastases and breast-conserving surgery: Secondary results of the INSEMA trial

A. DUJMOVIĆ More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy-primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R) study

K. ANTUNAC Advances in breast radiotherapy: Less is more!

M. SOČE Should we irradiate the IM Nodes: Settling the Issue

T. MLINARIĆ KOPRIVANAC

Repeat breast conservation with re-irradiation: What is the data and how do we do it?

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

12:50 – 13:10 Satellite Symposium: Pfizer

13:10 – 14:00 Lunch/Break

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

14:00 – 14:45

Satellite Symposium Astra Zeneca

14:45 – 15:25 Section 5.

I. BIONDIĆ Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0

M. PRUTKI Effect of preoperative breast MRI Staging on Local regional recurrence (LRR) in early stage Breast cancer: ALLiance AO11104/ACRIN6694

D. HUIĆ FDG-PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE ECOG-ACRIN EA1183

15:25 - 16:15 CLINICAL CONTROVERSIES:

Management of the Axilla in Multidisciplinary Care

R. ŽIC De-escalation of axillary surgery after NAC in clinically node positive patients

K. ANTUNAC De-Escalation of Regional Nodal Irradiation after NAC in Clinically Node Positive Patients

16:15 – 16:35 Coffee break

16:35 - 17:15 Section 6. YEAR IN THE REVIEW

Moderator: **Eduard Vrdoljak**

M. BAŠIĆ KORETIĆ: Early breast cancer

E. VRDOLJAK: Advanced breast cancer

17:15 - 17:30 WHAT WILL WE DO ON MONDAY MORNING?

17:30 Summary and Closing Remarks

17:35 End of the Symposium

